JP2017523796A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523796A5
JP2017523796A5 JP2017506955A JP2017506955A JP2017523796A5 JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5 JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5
Authority
JP
Japan
Prior art keywords
seq
following sequence
encephalitis virus
structural protein
equine encephalitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506955A
Other languages
English (en)
Japanese (ja)
Other versions
JP6824154B2 (ja
JP2017523796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/003997 external-priority patent/WO2016021209A1/en
Publication of JP2017523796A publication Critical patent/JP2017523796A/ja
Publication of JP2017523796A5 publication Critical patent/JP2017523796A5/ja
Application granted granted Critical
Publication of JP6824154B2 publication Critical patent/JP6824154B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506955A 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 Active JP6824154B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462035037P 2014-08-08 2014-08-08
US62/035,037 2014-08-08
US201462079128P 2014-11-13 2014-11-13
US62/079,128 2014-11-13
US201562101514P 2015-01-09 2015-01-09
US62/101,514 2015-01-09
US201562120569P 2015-02-25 2015-02-25
US62/120,569 2015-02-25
US201562198949P 2015-07-30 2015-07-30
US62/198,949 2015-07-30
PCT/JP2015/003997 WO2016021209A1 (en) 2014-08-08 2015-08-07 Virus like particle comprising modified envelope protein e3

Publications (3)

Publication Number Publication Date
JP2017523796A JP2017523796A (ja) 2017-08-24
JP2017523796A5 true JP2017523796A5 (OSRAM) 2018-09-06
JP6824154B2 JP6824154B2 (ja) 2021-02-03

Family

ID=55263499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506955A Active JP6824154B2 (ja) 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子

Country Status (6)

Country Link
US (1) US9969986B2 (OSRAM)
EP (1) EP3177720B1 (OSRAM)
JP (1) JP6824154B2 (OSRAM)
CN (1) CN106795513B (OSRAM)
TW (1) TWI720946B (OSRAM)
WO (1) WO2016021209A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013221187B9 (en) 2012-02-16 2018-01-04 Vlp Therapeutics, Inc. Virus like particle composition
CA2913832C (en) 2013-06-03 2023-07-04 Vlp Therapeutics, Llc A virus-like particle comprising a malaria antigen and use thereof as a malaria vaccine
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10744199B2 (en) 2013-10-11 2020-08-18 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Epstein-Barr virus vaccines
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
US10385101B2 (en) * 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106687590B (zh) 2014-09-11 2021-08-03 Vlp治疗公司 黄热病毒病毒样颗粒
BR112017014219A2 (pt) 2014-12-31 2018-03-06 The Usa As Represented By The Secretary Dept Of Health And Human Services vacinas à base de nanopartículas multivalentes
US10166281B2 (en) 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2017150683A1 (en) * 2016-03-04 2017-09-08 Vlp Therapeutics, Llc Zika virus virus like particle
US11020473B2 (en) * 2016-06-24 2021-06-01 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
CA3035443A1 (en) 2016-09-02 2018-03-08 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
US11129886B2 (en) 2017-03-28 2021-09-28 Children's Hospital Medical Center VLP-based bivalent Ebola vaccines and methods of making and using same
WO2018183488A1 (en) * 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
JP7412002B2 (ja) * 2017-12-20 2024-01-12 ブイエルピー・セラピューティクス・インコーポレイテッド アルファウイルスレプリコン粒子
US12311019B2 (en) 2018-02-07 2025-05-27 Imugene Limited Vaccine composition and uses thereof
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
WO2021210686A1 (en) 2020-04-17 2021-10-21 Vlp Therapeutics, Inc. Coronavirus vaccine
CA3174651A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
WO2022225057A1 (en) * 2021-04-23 2022-10-27 Vlp Therapeutics, Inc. Galectin-targeting immunotherapy
CN115466330B (zh) * 2021-06-10 2023-10-20 清华大学 一种基于病毒样颗粒呈递冠状病毒受体结合区的冠状病毒亚单位疫苗
US20230110201A1 (en) * 2021-07-26 2023-04-13 Beam Therapeutics Inc. Pseudotyped recombinant lyssaviruses for gene therapy
JP2025513920A (ja) * 2022-04-18 2025-04-30 Ｃｙｎ－Ｋバイオ株式会社 炎症性疾患の処置
CN116042657A (zh) * 2023-01-16 2023-05-02 上海复诺健生物科技有限公司 自复制信使核糖核酸疫苗
WO2025084276A1 (ja) * 2023-10-16 2025-04-24 Ｃｙｎ－Ｋバイオ株式会社 肥満の処置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
KR100251505B1 (ko) 1991-11-16 2000-05-01 장 스테판느 말라리아원충으로부터의 cs 및 hbsag 사이의 혼성 단백질(hybrid protein between cs from plasmodium and hbsag)
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
EP0854929A1 (en) 1995-09-27 1998-07-29 Medical Research Council Recombinant viruses incorporating a protease cleavable protein
EP1054973A1 (en) 1998-02-11 2000-11-29 Maxygen, Inc. Antigen library immunization
AU7072700A (en) 1999-08-23 2001-03-19 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CA2448908C (en) 2001-05-30 2008-03-18 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
US20050031592A1 (en) 2002-11-13 2005-02-10 Doolan Denise L. Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines
US7790181B2 (en) * 2003-05-29 2010-09-07 The United States Of America As Represented By The Secretary Of The Army Live attenuated viral vaccines for Eastern Equine Encephalitis virus
US20050214321A1 (en) 2003-12-01 2005-09-29 Dow Global Technologies Inc. Recombinant icosahedral virus like particle production in pseudomonads
ES2371175T3 (es) 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
JP4819792B2 (ja) 2005-02-16 2011-11-24 国立大学法人東京工業大学 改変されたウイルスカプシドタンパク質及びその使用
NZ590308A (en) 2005-06-08 2012-02-24 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of cancer by inhibiting the programmed cell death 1 (pd-1) pathway
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP2889309B1 (en) 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of pd-1 or pd-l1
AU2007291936B2 (en) 2006-08-30 2012-09-27 Artes Biotechnology Gmbh Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
CA2705787A1 (en) 2007-11-26 2009-06-25 Novartis Ag Methods of generating alphavirus particles
SG171828A1 (en) * 2008-11-26 2011-07-28 Us Gov Health & Human Serv Virus like particle compositions and methods of use
ES2582005T3 (es) * 2008-12-09 2016-09-08 Novavax, Inc. Proteínas F del RSV modificadas y métodos de su uso
EP2477650B8 (en) 2009-09-18 2019-10-09 FRAUNHOFER USA Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
WO2012172574A1 (en) * 2011-06-17 2012-12-20 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
CN102321639B (zh) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
HK1206366A1 (en) 2011-10-25 2016-01-08 佛罗里达海湾海岸大学理事会 Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
AU2013221187B9 (en) 2012-02-16 2018-01-04 Vlp Therapeutics, Inc. Virus like particle composition
CN108912215A (zh) 2012-04-02 2018-11-30 北卡罗来纳-查佩尔山大学 用于登革病毒表位的方法和组合物
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
CA2913832C (en) 2013-06-03 2023-07-04 Vlp Therapeutics, Llc A virus-like particle comprising a malaria antigen and use thereof as a malaria vaccine
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10060924B2 (en) 2014-03-18 2018-08-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
WO2016021209A1 (en) 2014-08-08 2016-02-11 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein e3
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
BR112017014219A2 (pt) * 2014-12-31 2018-03-06 The Usa As Represented By The Secretary Dept Of Health And Human Services vacinas à base de nanopartículas multivalentes
EP3309251A4 (en) 2015-06-12 2019-03-13 Mie University HUMAN PARAIN FLUENZA TYPE 2 VIRUS VIRUS VECTOR AND VACCINE
WO2016210127A1 (en) 2015-06-25 2016-12-29 Technovax, Inc. Flavivirus and alphavirus virus-like particles (vlps)
MY187459A (en) 2015-07-16 2021-09-23 Bharat Biotech Int Ltd Vaccine compositions
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Similar Documents

Publication Publication Date Title
JP2017523796A5 (OSRAM)
SG11202003746UA (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
ZA202002249B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP2019194236A5 (OSRAM)
JP2017048194A5 (OSRAM)
JP2018024670A5 (OSRAM)
EA201790630A1 (ru) Способы получения рибозидов
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
LT3577124T (lt) Nukleotido hemisulfato druska, skirta hepatito c virusui gydyti
JP2016525888A5 (OSRAM)
JP2019524645A5 (OSRAM)
EP3568155A4 (en) RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
JP2016153424A5 (OSRAM)
JP2017532302A5 (OSRAM)
JP2011527560A5 (OSRAM)
EA201890527A1 (ru) Терапевтические вакцины против hpv18
LT3512863T (lt) 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu
JP2014028813A5 (OSRAM)
EP3148566C0 (en) LONG SYNTHETIC PEPTIDES (SLP) FOR THERAPEUTIC VACCINATION PURPOSES AGAINST HEPATITIS B VIRUS INFECTION
EP4043031A3 (en) Zika viral antigen constructs
JP2013539454A5 (OSRAM)
WO2015052543A3 (en) Malaria vaccination
JP2017501211A5 (OSRAM)
JP2018116258A5 (OSRAM)
JP2018030858A5 (OSRAM)